Exosome RNA Exosome RNA Research & Industry News
Extracellular vesicles (EVs) continue to attract attention as potential diagnostic tools and therapeutic delivery systems. These tiny membrane-bound particles carry proteins, RNA, lipids, and other cargo between cells, making them valuable for biomarker discovery and drug delivery. However, one major challenge has been studying the surface molecules on individual EVs because they are extremely small, often only tens of nanometers in diameter.
Researchers at Ludwig-Maximilians-Universität Munich have developed a method called Flow-Induced Dispersion Analysis (FIDA) that may help solve this problem by providing a more detailed way to measure EV size and interactions with antibodies.
FIDA is a microfluidic technique that measures particle behavior in solution without attaching vesicles to a surface. This is important because immobilizing EVs can sometimes alter their properties or interfere with measurements.
The researchers used FIDA to study how antibodies bind to CD63, one of the best-known EV surface markers. CD63 is commonly used to identify extracellular vesicles and exosomes.
The team examined EVs from three different sources:
- Genetically engineered HEK cells producing CD63-eGFP EVs
- Engineered HEK cells producing CD63-NeonGreen-Fc EVs
- EVs derived from clonally expanded immortalized mesenchymal stromal cells (ciMSCs)
Using FIDA, the measured EV sizes ranged from approximately 40–90 nm. This was somewhat smaller than measurements obtained by Nanoparticle Tracking Analysis (NTA), which estimated sizes between 70–200 nm. The difference likely reflects the strengths and limitations of the analytical methods and possible detection of non-EV particles by NTA.
The study also quantified antibody binding efficiency. Engineered vesicles showed higher CD63 epitope abundance compared with ciMSC-derived EVs. When testing antibody loading to Fc-receptor domains, the researchers found optimal loading occurred at relatively low antibody concentrations.
As EV therapeutics move toward clinical applications, researchers need better quality control tools to verify vesicle identity, surface composition, and targeting capability. FIDA may provide a new way to evaluate EV-antibody interactions in real time while using relatively small sample amounts.
The authors suggest this technique could support EV standardization workflows, helping improve manufacturing consistency and characterization of future extracellular vesicle therapeutics.
As engineered EVs and exosomes continue advancing toward clinical use, methods like FIDA may become increasingly important for quality control, biomarker development, and therapeutic optimization.
